Jazz Pharmaceuticals JAZZ Accrued Marketing and Advertising Expenses
Accrued Marketing and Advertising Expenses at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedMarketingCostsCurrent.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's accrued marketing and advertising expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's accrued marketing and advertising expenses?
- Jazz Pharmaceuticals (JAZZ) reported accrued marketing and advertising expenses of $21.4M in Q1 2026.
- How has Jazz Pharmaceuticals's accrued marketing and advertising expenses changed year-over-year?
- Jazz Pharmaceuticals's accrued marketing and advertising expenses decreased by 5.0% year-over-year, from $22.53M to $21.4M.
- What is the long-term trend for Jazz Pharmaceuticals's accrued marketing and advertising expenses?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's accrued marketing and advertising expenses has grown at a 18.0% compound annual growth rate (CAGR), from $6.74M to $15.4M.